Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Cash And Cash Equivalents At Carrying Value of $251.3 thousand for the year ending 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -18.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from PROVECTUS BIOPHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), PROVECTUS BIOPHARMACEUTICALS, INC.'s Cash And Cash Equivalents At Carrying Value has declined by 91.0%.
- Historical annual values: Fiscal year 2025: $251.3 thousand | Fiscal year 2024: $307.4 thousand | Fiscal year 2023: $76.6 thousand | Fiscal year 2022: $21.6 thousand | Fiscal year 2021: $683.0 thousand | Fiscal year 2020: $97.2 thousand | Fiscal year 2019: $590.7 thousand | Fiscal year 2018: $51.0 thousand | Fiscal year 2017: $105.5 thousand | Fiscal year 2016: $1.17 million | Fiscal year 2015: $14.18 million | Fiscal year 2014: $17.39 million | Fiscal year 2013: $15.70 million | Fiscal year 2012: $1.22 million | Fiscal year 2011: $7.71 million | Fiscal year 2010: $8.09 million | Fiscal year 2009: $3.24 million | Fiscal year 2008: $2.80 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: